CJC-1295 vs Tesamorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Egrifta, TH9507
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. One of the few peptides with FDA approval.
Key Comparison Insights
- Tesamorelin is FDA approved, while CJC-1295 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to CJC-1295 (Human Trials).
Detailed Comparison
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 2 mg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | Indefinite for approved indication |
| Best Time to Take | Before bed | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | FDA approved based on trials showing significant reduction in trunk fat (up to 18%) in HIV lipodystrophy patients. Studies also show improvements in lipid profiles, particularly triglycerides. Research ongoing for cognitive benefits and NAFLD treatment. |
Frequently Asked Questions: CJC-1295 vs Tesamorelin
What is the difference between CJC-1295 and Tesamorelin?
CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. one of the few peptides with fda approval. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 or Tesamorelin?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 is typically used for growth hormone purposes, while Tesamorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 and Tesamorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 and Tesamorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of CJC-1295 and Tesamorelin is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.